Sanofi has received separate offers from private equity firms Clayton Dubilier & Rice and PAI Partners to buy its consumer health unit, which could be worth 15 billion euros ($16.74 billion) or more, Bloomberg News reported Tuesday.
The drugmaker may decide to pursue a spin-off if the offers are not attractive, Bloomberg reported, citing people familiar with the matter.
PAI is trying to block a British Columbia investment management firm from obtaining a licence. To support its bid, the company has also been in talks to bring the Abu Dhabi Investment Authority and Singapore’s sovereign wealth fund GIC Pte Ltd into the consortium, the report added.
As announced in October 2023, Sanofi is reviewing potential scenarios for the separation of its consumer healthcare business through a transaction no later than the fourth quarter, a Sanofi spokesperson told Reuters.
The spokesperson also said that no decision has been made yet, and we expect to choose the best option for Sanofi and its stakeholders in the coming months.
(1 dollar = 0.8962 euro)
